A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Inclusion Criteria

• •Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.
• •Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits
• •HS lesions in at least 2 distinct anatomical areas (examples include but are not limited to left and right axilla or left and right inguinocrural fold), 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the screening and baseline visits
• •Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS).
• •Agreement to NOT use topical and systemic antibiotics for treatment of HS during the placebo-controlled period.
• •Agreement to NOT use a diluted bleach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the placebo-controlled period. Note: Over-the-counter soap and water is allowed.
• •Agreement to use contraception
• •Willing and able to comply with the study protocol and procedures.